We recently reported that RASSF1A acts both as a tumor and metastasis gene suppressor in patients with early stage non-small cell lung cancer (NSCLC) [1, 3], RASSF1A both restricting activation of YAP, one of the terminal target of the Hippo pathway, and stimulating activation of RhoB, a small anti-migratory GTPase protein, via GEF-H1, its GDP/GTP exchange factor [3]. The gene discussed is YAP1; the disease is neoplasm.